Nitrogen-Containing Bisphosphonate Carbon Dots with High Affinity to Calcium-Based Biomaterials for Suppression of Osteoclasts

BioChip Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Language: Английский

---

Sustained Release of HIF-2α Inhibitors Using Biodegradable Porous Silicon Carriers for Enhanced Immunogenic Cell Death of Malignant Merkel Cell Carcinoma

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer with limited treatment options, often associated polyomavirus (MCPyV) and marked by hypoxic tumor microenvironments that promote resistance to therapies. Belzutifan, an FDA-approved hypoxia-inducible factor-2α (HIF-2α) inhibitor, has shown promise in inhibiting growth; however, its clinical efficacy hindered low solubility, rapid clearance, bioavailability. In this study, we present strategy using porous silicon (pSi) microparticles nanoparticles as carriers for the sustained delivery of benzoate MCC cells. The pSi were engineered securely encapsulate gradually release belzutifan, overcoming limitations free drug administration. Microparticles provided extracellular release, while enabled efficient intracellular delivery, enhancing HIF-2α inhibition. Moreover, use biodegradable particles enables long-term consistent belzutifan over 10 days vitro single dose administration microenvironment, rapidly deactivated within 1 day postadministration. studies demonstrated significant immunogenic death (ICD) cells, cytosolic localization HMGB1 elevated expression pro-inflammatory cytokines well strong upregulation TLR9. Particularly, increased TLR9 both lines carrier reinforces immune activation through toll-like receptor signaling, innate adaptive responses microenvironment. These findings indicate not only enhance belzutifan's stability profile also amplify antitumor Our results suggest belzutifan-loaded offer potent targeted therapeutic MCC, potentially addressing key challenges immunotherapy combining inhibition robust activation. This platform highlights universal utility pSi-based systems advance implications broader

Language: Английский

---

Role of liposomes in chemoimmunotherapy of Breast cancer

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 43

Published: Feb. 19, 2025

In the dynamic arena of cancer therapeutics, chemoimmunotherapy has shown tremendous promise, especially for aggressive forms breast like triple-negative (TNBC). This review delves into significant role liposomes in enhancing effectiveness by leveraging cancer-specific mechanisms such as induction immunogenic cell death (ICD), reprogramming tumor microenvironment (TME), and enabling sequential drug release. We examine innovative dual-targeting that capitalize on heterogeneity, well pH-sensitive formulations offer improved control over delivery. Unlike prior analyses, this directly links advancements preclinical research-such PAMAM dendrimer-based nanoplatforms RGD-decorated liposomes-to clinical trial results, highlighting their potential to revolutionize TNBC treatment strategies. Additionally, we address ongoing challenges related scalability, toxicity, regulatory compliance, propose future directions personalized, immune-focused nanomedicine. work not only synthesizes latest research but also offers a framework translating liposomal from laboratory practice.

Language: Английский

---

Construction of Chitosan Oligosaccharide-Coated Nanostructured Lipid Carriers for the Sustained Release of Strontium Ranelate

Tissue Engineering and Regenerative Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Language: Английский

---

Vascular embolic nanobiomaterials for efficient tumor treatment

Tissue and Cell, Journal Year: 2025, Volume and Issue: 96, P. 102954 - 102954

Published: May 7, 2025

Language: Английский

---